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Background: Gambogic acid (GA), a potent anticancer agent, is limited in clinical   administration 
due to its poor water solubility. The aim of this study was to explore a drug delivery system 
based on magnetic Fe3O4 nanoparticles (MNP-Fe3O4) conjugated with GA to increase water 
solubility of the drug and enhance its chemotherapeutic efficiency for pancreatic cancer.
Methods: GA was conjugated with the MNP-Fe3O4 colloidal suspension by mechanical 
absorption polymerization to construct GA-loaded MNP-Fe3O4, which acted as a drug delivery 
system.
Results: Combination therapy with GA and MNP-Fe3O4 induced remarkable improvement 
in anticancer activity, which was demonstrated by optical microscopic observations, MTT 
assay, and nuclear DAPI staining. Furthermore, the possible signaling pathway was explored 
by Western blot. In Capan-1 pancreatic cancer cells, our observations demonstrated that this 
strategy could enhance potential anticancer efficiency by inducing apoptosis. The mechanisms 
of the synergistic effect may be due to reducing protein expression of Bcl-2 and enhancing that 
of Bax, caspase 9, and caspase 3.
Conclusion: These findings demonstrate that a combination of GA and MNPs-Fe3O4 represents 
a promising approach to the treatment of pancreatic cancer.
Keywords: gambogic acid, pancreatic cancer, magnetic nanoparticles, drug delivery system, 
apoptosis
Introduction
With one of the highest mortality-to-incidence ratios, pancreatic cancer is the eighth 
leading cause of cancer-related death in men worldwide and the ninth in women.1 The 
disease is usually detected at an advanced stage, carries a poor prognosis regardless of 
treatment, and is associated with debilitating symptoms. After initial diagnosis, most 
patients have a median survival with treatment of about 6 months.1 Even in cases where 
the cancer is diagnosed at an early resectable stage, 5-year survival is still only 22%.2 
Advances in treating pancreatic cancer have been few and modest. Pancreatic cancer 
is well recognized as an extremely challenging disease on multiple fronts, and the use 
of chemotherapy has been shown to improve survival.3 There is now more emphasis 
on early chemotherapy in locally advanced pancreatic cancer and combination che-
motherapy in metastatic disease.1
Gambogic acid (GA), a natural compound extracted from gamboges, has recently 
been identified as a potent anticancer agent. Recent studies have shown that GA can 
inhibit growth of a wide variety of tumor cells, including hepatoma, pulmonary car-
cinoma, gastric cancer, and breast cancer.4–7 However, little is known about the effect International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of GA in pancreatic cancer. In addition, the therapeutic 
effect of GA is limited due to low water solubility. Therefore, 
efforts should be made to develop new delivery techniques 
to increase water solubility which could alter its biodistribu-
tion, enhance its deposition in tumor sites, and improve its 
therapeutic efficacy.8
Various types of nanosized drug carriers, such as lipo-
somes, polymeric micelles, dendrimers, superparamagnetic 
iron oxide crystals, semiconductor nanomaterials, and col-
loidal gold, have been investigated in cancer therapy in order 
to minimize the side effects of anticancer therapy, improve 
water solubility of drugs, and enhance the antitumoral effi-
cacy of targeted therapies.9,10 The most promising materials 
are magnetic nanoparticles. Magnetic Fe3O4 nanoparticles 
(MNP-Fe3O4), a biocompatible and superparamagnetic 
nanomaterial with satisfactory chemical stability and low 
toxicity, are widely used as targeted drug carriers with target 
orientation and sustained-release properties.11–15
In view of this research, we were inspired to explore 
a drug delivery system for GA based on MNP-Fe3O4 to 
increase its water solubility and enhance its chemotherapeutic 
efficiency. To the best of our knowledge, no study to date 
has been carried out of combination therapy with GA and 
MNP-Fe3O4 for pancreatic cancer. We have investigated the 
anticancer efficacy of this combination in pancreatic cancer 
for the first time. In this study, GA was loaded onto MNP-
Fe3O4 (GA-MNP-Fe3O4) as a drug delivery system, and we 
then identified the cytotoxic effects of GA-MNP-Fe3O4 in 
Capan-1 pancreatic cancer cells, investigated the apoptosis 
induced, and further measured the expression of apoptosis-
related proteins, including caspase 3, caspase 9, Bax, and 
Bcl-2, to elucidate the possible mechanisms involved.
Materials and methods
Main chemicals and apparatus
Iron (II) chloride tetrahydrate (FeCl2 ⋅ 4H2O) and iron (III) 
chloride hexahydrate (FeCl3 ⋅ 6H2O) were obtained from Sinop-
harm Chemical Reagent Co Ltd (Shanghai, China). Ammo-
nium hydroxide and citric acid were acquired from Shanghai 
Lingfeng Chemical Reagent Co Ltd (Shanghai, China). GA 
(Kanion Pharmaceutical Co Ltd, Jiangsu, China) was dissolved 
in dimethyl sulfoxide (Sigma Aldrich, St Louis, MO), stored 
at -20°C, and then diluted as needed in RPMI-1640 medium 
(Gibco/BRL, Carlsbad, CA).   Monoclonal antibodies, including 
caspase 3, Bax, Bcl-2, caspase 9, and β-actin, were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). 
The horseradish peroxidase-conjugated IgG antibody was 
obtained from   Nanjing KeyGen Biotech Inc (Nanjing, China).   
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bro-
mide (MTT) and 4, 6-diamidino-2-phenylindole (DAPI) were 
obtained from Sigma, and stored in the dark. All other reagents 
were of analytical grade. The transmission electron micro-
scopic images were obtained using a JEM-2100 transmission 
electron microscope. The fluorescent microscopic images were 
shot on an Olympus IX51 inverted microscope. The optical 
density at 492 nm was recorded using a multiwell spectropho-
tometer reader (Thermo Labsystems, Vantta, Finland).
synthesis of magnetic Fe3O4 nanoparticles
Magnetic Fe3O4 nanoparticles were prepared by coprecipi-
tation of Fe (III) and Fe (II) with ammonium hydroxide in 
a nitrogen environment. In a typical synthetic experiment, 
FeCl3 ⋅ 6H2O 2.61 g and FeCl2 ⋅ 4H2O 1.04 g were dissolved 
in 100 mL of deionized water and heated to 80°C, followed 
by the slow addition of 10 mL of ammonium hydroxide with 
vigorous stirring for 20 minutes. Black Fe3O4 precipitates 
were obtained and washed immediately with distilled water 
five times by magnetic separation. The precipitates were then 
dispersed in distilled water with 1.25 g citric acid, which 
acted as a stabilizer of the colloidal nanocrystallites, with 
vigorous stirring for 90 minutes. The products, ie, citric 
acid-coated MNP-Fe3O4, were cooled to room temperature 
and extracted by a magnet. Finally, after being washed with 
ethanol and finally with deionized water, the products were 
lyophilized and stored at room temperature.
Preparation of gA-loaded magnetic  
Fe3O4 nanoparticles
Before being applied in the present experiment, MNP-Fe3O4 
were well distributed in RPMI-1640 medium with 10% 
heated inactivated fetal bovine serum using ultrasound treat-
ment in order to obtain a MNP-Fe3O4 colloidal suspension. 
As previously reported,16 GA at different concentrations was 
conjugated with the MNP-Fe3O4 colloidal suspension by 
mechanical absorption polymerization at 4°C for 48 hours to 
construct GA-loaded MNP-Fe3O4 (GA- MNP-Fe3O4), which 
acted as a drug delivery system.
cell culture
The Capan-1 pancreatic cancer cells, obtained from the 
Shanghai Institute of Cell Biology, Chinese Academy of 
Sciences, were cultured in RPMI-1640 supplemented with 
10% heat-inactivated fetal bovine serum, 100 U/mL penicil-
lin, and 100 µg/mL streptomycin at 37.0°C in humidified 
air with 5% CO2. The cells were in log phase prior to the 
following experiments.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Assay of anticancer activity
The cytotoxicity of MNP-Fe3O4, GA, and GA-MNP-Fe3O4 
was studied against Capan-1 pancreatic cancer cells with 
MTT assays. Cells at 1 × 105/mL were seeded in 96-well 
plates and incubated for 24 hours. The growth medium was 
then replaced with 200 µL of the prepared medium containing 
free GA and GA-MNP-Fe3O4, in which the GA concentra-
tion was 0, 0.25, 0.5, 1.0, and 2.0 µmol/L. The cells were 
also treated by MNP-Fe3O4 alone to evaluate cytotoxicity. 
Cells without any treatment were used as the control group. 
The cells were further incubated for 48 hours, and the rela-
tive anticancer activity was assessed using MTT assays. In 
brief, MTT solutions were added after the treatments and 
incubated for an additional 4 hours. Dimethyl sulfoxide was 
added to solubilize the formazan crystal, and optical density 
at 492 nm was recorded. The cell viability fraction (%) was 
calculated as:
     OD492 nm in test cells/OD492 nm in control cells × 100%
DAPI staining
The cells were treated according to the above methods for 
48 hours, and then fixed with 4% polyoxymethylene prior to 
washing with phosphate-buffered saline. The washed cells 
were then stained with DAPI 1 mg/mL for 15 minutes in the 
dark. The staining images were recorded using the fluorescent 
microscope.
Western blot analysis
After the different treatments, expression of apoptosis-
related proteins was detected by Western blot. In brief, total 
protein was isolated and subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, and transferred to a 
polyvinylidene fluoride membrane. After being blocked, the 
membrane was incubated with primary polyclonal antibodies, 
either anti-caspase 3, Bax, Bcl-2, caspase 9, or anti-β-actin 
overnight at 4°C, and subsequently incubated with horserad-
ish peroxidase-conjugated IgG antibody as the secondary 
antibody for one hour at room temperature. The protein 
bands were detected by an enhanced ECL detection system 
(Amersham, UK). After normalization by the corresponding 
expression of β-actin, protein expression levels of caspase 3, 
Bax, Bcl-2, and caspase 9 were determined by densitometry 
scans.
statistical analysis
All the data are presented as means ± standard deviations. 
The F-test was used for significance testing, and P , 0.05 
was considered to be statistically significant. All tests were 
performed using SPSS (v 13.0, SPSS Inc, Chicago, IL).
Results and discussion
characterization of magnetic Fe3O4 
nanoparticles
The synthesized MNP-Fe3O4 capped with citric acid were 
characterized by transmission electron microscopy. As shown 
in Figure 1, MNP-Fe3O4 were observed to have a spherical 
shape, with a diameter of about 20 nm. The size distribution 
of these MNP-Fe3O4 is shown in Figure 2. It has suitable 
dimensions to escape renal rapid excretion, as well as to avoid 
components of the reticular endothelial system, thus facilitat-
ing potentially passive targeting of drugs to tumors via the 
enhanced permeation and retention effect and active targeting 
with target orientation of magnetic field, then increasing the 
accumulation of drugs in tumor cells after endocytosis.17
Anticancer activity in vitro
GA exhibits potent anticancer activity in many kinds of 
cancer cells.4–7 However, whether or not GA induces apop-
tosis of Capan-1 pancreatic cancer cells, and the molecular 
mechanisms involved, is not clear. In addition, the therapeutic 
effect of GA is limited due to low water solubility (,1 µg/
mL).8 Therefore, we sought to identify the potential benefit of 
combination therapy using GA-MNP-Fe3O4 as a drug carrier 
for pancreatic cancer and whether MNP-Fe3O4 could promote 
the apoptosis induced by GA. In our study, no precipitation of 
GA was noted in the colloidal suspension of the GA-MNP-
Fe3O4 drug delivery system after 2 months of storage, which 
indicates that the solubility of GA was improved and drug 
delivery was stable during storage at 4°C. To explore the 
anticancer efficiency of the GA-  MNP-Fe3O4 drug delivery 
Figure 1 Transmission electron microscope image of magnetic Fe3O4 nanoparticles.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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system, we cultured Capan-1 pancreatic cancer cells with 
free GA at different concentrations (0, 0.25, 0.5, 1.0, and 
2.0 µmol/L), MNP-Fe3O4 loading GA with equivalent GA 
concentration for 48 hours. The cytotoxicity results were 
estimated by MTT assay and are shown in   Figure 3. Cyto-
toxicity testing of a nanomaterial is the first-level evaluation 
before its biomedical application. When treated by MNP-
Fe3O4 20 µg/mL, about 95% of the cells survived (Figure 3, 
pink line), which is consistent with our previous report.11–16 
The results suggested that the MNP-Fe3O4 capped with 
citric acid synthesized in this study lack cytotoxicity, thus 
ensuring a wide potential range of applications in the field of 
biomedical science and cancer therapy. Compared with GA 
alone (Figure 3, red line), the viability of Capan-1 pancreatic 
cancer cells treated by GA-MNP-Fe3O4 obviously decreased 
(Figure 3, green line). Meanwhile, our results also indicate 
that lethality increased with increasing concentrations of GA, 
suggesting a dose-dependent effect in vitro. The increased 
cytotoxicity may be due to improved GA cellular uptake by 
the GA-MNP-Fe3O4 drug delivery system, which increases 
the water solubility of GA through the endocytosis pathway 
and then induces release of GA from the MNP-Fe3O4 to pro-
mote efficient cell killing, which is a common characteristic 
of nanoparticle-based drug delivery systems.18,19
In addition, as shown in the insets of Figure 3, the 
  optical microscopic observations confirm the MTT results. 
The Capan-1 pancreatic cancer cells without any treatment 
attached to the plate with a normal elongated shape. Notably, 
the cells treated with MNP-Fe3O4 showed no morphological 
changes. If these cells are in a lethal state, they detach from 
the plate and assume a smaller and spherical morphology. It 
is obvious that GA and GA-MNP-Fe3O4 would cause more 
significant morphological changes, indicating the increasing 
probability of cell death, and the GA-MNP-Fe3O4 group was 
even more effective. Cooperation of MNP-Fe3O4 and GA 
could kill even more cancer cells, indicating their synergistic 
anticancer activity.
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Figure 3 cytotoxic effect of gA or gA-loaded MNP-Fe3O4 against the capan-1 pancreatic cancer cells. Inset: Microscopic images of the capan-1 cells after different 
treatments for 48 hours. (A) untreated cells as control, (B) MNP-Fe3O4, (C) gA alone, and (D) gA-loaded MNP-Fe3O4. 
Notes: The concentrations of gA, MNP-Fe3O4 are 1 µmol/L and 20 µg/mL, respectively. Data are expressed as means ± standard deviations (n = 3).
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Morphologic characterization of 
apoptosis
Apoptosis is an important metabolic step in regulating 
the number and growth of cells. If apoptosis is blocked, 
metabolism becomes disordered, and tumors develop and 
grow. Most anticancer agents exert their anticancer effects by 
inducing apoptosis.16 Recently, MNP-Fe3O4 have been widely 
used as targeted drug carriers to enhance the efficiency of 
anticancer drug delivery based on an ability for target ori-
entation and sustained-release properties.20 Our previous 
studies have demonstrated the synergistic effect between 
MNP-Fe3O4 and anticancer drugs in terms of intracellular 
accumulation in cancer cells to induce apoptosis.11–16 
Nuclear DAPI staining was performed in the present 
study to explore the mechanism of the distinct improvement 
in anticancer activity induced by synergism between MNP-
Fe3O4 and GA. To confirm the existence of apoptosis, a study 
of the morphological changes in the cells was undertaken. 
Evaluation of normal or apoptotic cells depends on their 
morphological characterization. Normal nuclei (smooth 
nuclear) and apoptotic nuclei (condensed or fragmented 
chromatin) are easily distinguished. As shown in Figure 4, 
the nuclear morphology analysis showed characteristic apop-
totic changes, such as chromatin condensation, convoluted 
nuclei with cavitations, fragmentation of the nucleus, and 
apoptotic bodies in the Capan-1 pancreatic cancer cells 
after treatment with both GA and GA-MNP-Fe3O4. There 
was almost no evidence of apoptosis in the control group 
(Figure 4A) and in the MNP-Fe3O4 group (Figure 4B). When 
the cells were treated with GA-MNP-Fe3O4 (Figure 4D), 
typical apoptotic morphology was more apparent than in 
cells treated with GA alone (Figure 4C). These findings 
strongly indicate that the synergistic effect of MNP-Fe3O4 
and GA killed the cancer cells by inducing apoptosis rather 
than necrosis.
expression of Bax, Bcl-2, caspase 9, and 
caspase 3 proteins
Next, we studied the molecular mechanism of apoptosis 
induced by the synergistic effect of MNP-Fe3O4 and GA in 
Capan-1 pancreatic cancer cells. The antiapoptotic protein, 
Bcl-2, has been associated with inhibition of apoptosis and 
cell survival mechanisms. The Bax protein is a proapoptotic 
member of this family, and its increased expression is often 
associated with increased apoptosis in target cells.21 Apoptosis 
is the consequence of a series of precisely regulated events that 
are frequently altered in tumor cells. In general, the sequence 
of events has been broadly categorized into two pathways, ie, 
the extrinsic pathway, which involves activation of the tumor 
necrosis factor/Fas death receptor family, and the intrinsic 
pathway, which involves the mitochondria. In both pathways, 
an apoptotic death stimulus results in activation of caspases, 
the major executioners in this process, either directly or via 
activation of the mitochondrial death program.16 Therefore, 
we examined changes in the expression levels of apoptosis-
regulating proteins, including caspase 3, caspase 9, Bax, and 
Bcl-2, by Western blot to explore possible signaling pathways 
through which GA-MNP-Fe3O4 induced distinct improvement 
in anticancer activity. As shown in Figure 5, when the Capan-1 
pancreatic cancer cells were treated with GA and GA-MNP-
Fe3O4 for 48 hours, levels of caspase 3, caspase 9, and Bax 
protein were significantly upregulated compared with the 
control group. Meanwhile, upregulated levels in the GA-MNP-
Fe3O4 group were slightly higher than those in the GA group 
(P , 0.05). However, they were not obviously altered when 
the cells were treated with MNP-Fe3O4 alone (P . 0.05). In 
contrast, compared with the control group, the levels of Bcl-2 
protein in cells treated with GA and GA-MNP-Fe3O4 were 
both significantly downregulated. Furthermore, the level of 
Bcl-2 in the GA-MNP-Fe3O4 group was lower than that in GA 
group, and was also not obviously altered when the cells were 
ABCD
Control group MNP-Fe3O4 GA GA-MNP-Fe3O4
Figure 4 Nuclear morphologic changes of the capan-1 pancreatic cancer cells after different treatment for 48 hours. (A) untreated cells as control, (B) MNP-Fe3O4,   
(C) gA alone, and (D) gA-loaded MNP-Fe3O4. 
Notes: The concentrations of gA and MNP-Fe3O4 are 1 µmol/L and 20 µg/mL, respectively. Magnification folds ×400. Arrows indicate cells with apoptotic nuclear 
condensation and fragmentation.
Abbreviations: gA, gambogic acid; MNP-Fe3O4, magnetic Fe3O4 nanoparticles.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1934
Wang et al
treated with MNP-Fe3O4 alone (P . 0.05). In our study, the 
ratio of Bax/Bcl-2 protein expression increased dramatically 
when the Capan-1 pancreatic cancer cells were treated with 
GA-MNP-Fe3O4. A large amount of evidence has shown that 
the sensitivity of cells to the apoptotic stimulus is determined 
by the relative ratio of proapoptotic and antiapoptotic mem-
bers of the Bcl-2 family, ie, the mitochondrial-related death 
switch.22 We deduce that upregulated Bax leads to disruption 
of the integrity of the mitochondrial membrane and promotes 
release of cytochrome c from the mitochondria, resulting 
in caspase 9/caspase 3 activation and DNA fragmentation. 
Caspase activation is generally considered to be a hallmark 
of apoptosis, and caspase 3 is the main effector caspase that is 
involved in apoptosis.23 Thus, the ratio of Bcl-2/Bax might be 
a critical factor in the cell threshold for undergoing apoptosis 
induced by GA-MNP-Fe3O4. Collectively, GA combined with 
MNP-Fe3O4 has been shown to elevate the Bax/Bcl-2 ratio 
dramatically, enhance caspase 9/caspase 3 activity, and further 
stimulate the initiation of mitochondrial apoptosis signaling.
Based on the above studies, Figure 6 schematically illus-
trates the possible processes by which the GA-MNP-Fe3O4 
drug delivery system induces a distinct improvement in 
anticancer activity. Firstly, GA was conjugated with the 
MNP-Fe3O4 colloidal suspension by mechanical absorption 
polymerization to construct GA-MNP-Fe3O4, which acted as 
a drug delivery system. This drug delivery system increased 
the water solubility of GA and enhanced its chemotherapeutic 
efficiency after endocytosis, and so has tremendous potential 
for application in cancer therapy by inducing apoptosis, a 
preferred mode for killing cancer cells in cancer therapy, and 
is induced synergistically, resulting in a distinct improvement 
in anticancer activity.
Conclusion
A GA-MNP-Fe3O4 drug delivery system was developed to 
increase the water solubility of GA and enhance its chemo-
therapeutic efficiency. MNP-Fe3O4 enhanced the anticancer 
activity of GA in Capan-1 pancreatic cancer cells by inducing 
apoptosis, and the synergistic effect may be due to regulation 
of various antiapoptotic and proapoptotic gene products, 
including Bax, Bcl-2, caspase 9, and caspase 3. All these 
characteristics demonstrate that combination therapy with 
GA and MNP-Fe3O4 represents a promising strategy in the 
treatment of pancreatic cancer.
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